Outcome of endometrial ablation therapy with cavaterm thermal balloon in patients with abnormal uterine bleeding
The purpose of this retrospective study was to evaluate the long-term outcome of endometrial ablation (EA) therapy with Cavaterm Thermal Balloon in patients with abnormal uterine bleeding (AUB). The retrospective cross-sectional study was performed on 227 patients referred to Shahid Sadoughi Hospital in Yazd, Iran with AUB undergoing EA therapy. The data collection tool was a questionnaire containing demographic profiles, menstrual status, treatment success, postoperative complications, and patient satisfaction during the follow-up of 6 months to 7 years after surgery. The treatment response was measured by reduced menstrual bleeding (spotting, normal menstruation, amenorrhea, hypomenorrhea and oligomenorrhea) during the first 6 months after surgery and later. The mean age of participants was 45.9±5.9 years, and the mean follow-up duration was 21.2±13.2 months. The rate of treatment response was received for 95% in the first 6 months and for 92.1% later; the prevalence of amenorrhea was 41.2%; and the patient satisfaction rate at the end of the follow-up was 89.2%. Dysmenorrhea disappeared in 32.6% of patients. 73.2% of patients wanted to preserve the uterus. Moreover, 1.4% of patients were pregnant in the follow-up period. Up to the end of the follow-up, 4 (1.9%) patients were treated by hysterectomy due to direct result of treatment failure. The results of this study showed that the EA surgery with Cavaterm thermal balloon was an effective treatment for the AUB. The patient satisfaction rate was favorable and the procedure is safe and is associated with a very low rate of postoperative adverse events. Results indicate that EA surgery is more effective for older patients and less effective for women with myomas, endometrial polyps, adenomyosis and an enlarged uterus. Assessment of these clinical parameters should be considered as a contraindication for EA surgery in patients with AUB.